Tao Wang

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 6

Top Topics

Kidney Transplantation

Endoplasmic Reticulum Stress

High Throughput

Tyrosine Kinase

Top Venues

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Caroline Taylor, Kamai M Patterson, Devira Friedman, Silvia M Bacot, Gerald M Feldman, Tao Wang
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer. Cancers 16 (17) (2024)
Tao Wang, Desirée Denman, Silvia M Bacot, Gerald M Feldman
Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 10 (5) (2022)
Shen Luo, Keisha Melodi McSweeney, Tao Wang, Silvia M Bacot, Gerald M Feldman, Baolin Zhang
Defining the right diluent for intravenous infusion of therapeutic antibodies. mAbs 12 (1) (2021)
Taylor A Harper, Silvia M Bacot, Christie-Jane Fennell, Rebecca L Matthews, Christina Zhu, Peng Yue, Alexander Benton, Devira Friedman, Adovi Akue, Mark A KuKuruga, Shiowjen Lee, Tao Wang, Gerald M Feldman
IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses. International journal of molecular sciences 22 (21) (2021)
Silvia M Bacot, Taylor A Harper, Rebecca L Matthews, Christie Jane Fennell, Adovi Akue, Mark A KuKuruga, Shiowjen Lee, Tao Wang, Gerald M Feldman
Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy. International journal of molecular sciences 21 (23) (2020)
Peng Yue, Taylor A Harper, Silvia M Bacot, Monica Chowdhury, Shiowjen Lee, Adovi Akue, Mark A Kukuruga, Tao Wang, Gerald M Feldman
BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways. Oncoimmunology 8 (1) (2018)